Kringle Pharma, Inc. (TYO:4884)

Market Cap	2.20B -62.3%
Revenue (ttm)	73.00M +1.4%
Net Income	-920.00M
EPS	-130.47
Shares Out	7.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,400
Open	297.00
Previous Close	297.00
Day's Range	297.00 - 320.00
52-Week Range	287.00 - 917.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Kringle Pharma

Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4884

Financial Performance

In fiscal year 2025, Kringle Pharma's revenue was 72.00 million, a decrease of -10.00% compared to the previous year's 80.00 million. Losses were -916.00 million, 21.2% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error